Wordt geladen...
A104 COST-EFFECTIVENESS OF INFLIXIMAB BIOSIMILAR FOR THE MANAGEMENT OF CROHN’S DISEASE
BACKGROUND: Infliximab is an anti-TNF therapy with proven efficacy for the induction and maintenance of remission in patients with Crohn’s disease (CD). An infliximab biosimilar, CT-P13 (marketed as Inflectra), has recently been introduced that could potentially result in large cost-savings for this...
Bewaard in:
| Gepubliceerd in: | J Can Assoc Gastroenterol |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507792/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy008.105 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|